Skip to content
Frontiers
Search

Review

Frontiers in Chemical Biology ·

Volume 4 - 2026 | https://doi.org/10.3389/fchbi.2025.1729615

Receptor-targeted technetium-99m radiopharmaceuticals: increasing access to molecular imaging in healthcare

  • Michelle T. Ma1*corresponding author
  1. School of Biomedical Engineering and Imaging Sciences, King’s College London, St Thomas’ Hospital, London, United Kingdom
Article metrics0 viewsView details
PDFCiteMetrics

Abstract

The γ-emitting radionuclide, technetium-99m (99m Tc), is widely accessible from 99m Tc generators, and is routinely incorporated into diagnostic imaging radiopharmaceuticals that measure perfusion or anatomical process in disease. There is potential to expand the use of 99m Tc to molecular radiopharmaceuticals, and leverage well-established and existing nuclear medicine infrastructure and resources (including nuclear reactor and 99m Tc generator supply chains, radiopharmacies, γ-scintigraphy and SPECT cameras, and trained nuclear medicine staff) to increase patient access to the benefits of receptor-targeted molecular imaging, particularly in oncology. To achieve this, suitable chemistry is required to develop new 99m Tc-labelled radiopharmaceuticals that incorporate 99m Tc into biomolecules. This review describes how existing 99m Tc chemistry has recently been applied to such innovations: chelator and ligand motifs (including mercapto-peptide, amine oxine, phosphine, isonitriles) that are already used for kit-based synthesis of 99m Tc perfusion agents have been derivatised with biomolecular pharmacophores for receptor-targeted molecular imaging. Recent clinical trials have established an evidence basis illustrating the utility of these new receptor-targeted 99m Tc radiopharmaceuticals. This work also describes the potential for an economical companion “theranostic” approach with the β - -emitter, rhenium-188 (188 Re), which can also be produced using generator technology. Initial preclinical and clinical studies have demonstrated that chemically analogous 99m Tc and 188 Re radiotracers show highly similar biodistribution patterns.

Keywords

Introduction

The advent of molecular radiopharmaceuticals (Sullivan et al., 2024) has been transformative in treatment for neuroendocrine cancer (Strosberg et al., 2017) and metastatic castration-resistant prostate cancer (Sartor et al., 2021). These radiopharmaceuticals (or tracers) consist of a radionuclide appended to a pharmacophore or biomolecule that targets receptors over-expressed on the surface of cancer cells. There are many metallic radionuclides that have utility for molecular diagnostic imaging or systemic radiotherapy. These radioactive metal centres are attached to biomolecules via chelators (Jackson et al., 2020).

In a “theranostic” approach with pairs of “look and treat” radiopharmaceuticals a radioactive imaging tracer first provides a whole body diagnostic imaging scan of receptor expression in a patient (Langbein et al., 2019; Weber et al., 2023; Bodei et al., 2022). If the scan shows that the patient’s disease is positive for the target receptor, a second radiotherapeutic tracer can be administered to the patient. For both the imaging and therapeutic tracers, the same pharmacophore is employed to enable delivery of the radioactive cargo to diseased tissue (Sullivan et al., 2024; Strosberg et al., 2017).

In neuroendocrine cancer, the somatostatin 2 receptor (SSTR2) is targeted by 68Ga-DOTA-octreotate (Figure 1), (DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) for diagnostic PET (Positron Emission Tomography) imaging, and 177Lu-DOTA-octreotate for delivery of a cytotoxic does of β--irradiation for systemic radiotherapy (Strosberg et al., 2017). In the past - and indeed still in centres where PET imaging is unavailable - 111In-DTPA-octreotide (DTPA, diethylenetriaminepentaacetic acid) has been used to diagnose SSTR2-positive neuroendocrine cancers using γ-scintigraphy or SPECT (Single Photon Emission Computed Tomography) imaging (Shi et al., 1998).

Structures of DOTA-octreotate (top), which is used to deliver <sup>68</sup>Ga<sup>3+</sup> or <sup>177</sup>Lu<sup>3+</sup> to SSTR2-expressing neuroendocrine tumours, and PSMA-617 and PSMA-11 (bottom), containing the DOTA and HBED chelators respectively. <sup>177</sup>Lu-PSMA-617 and <sup>68</sup>Ga-PSMA-11 are theranostic radiopharmaceuticals used for treatment of PSMA-expressing prostate cancer.
Figure 1. Structures of DOTA-octreotate (top), which is used to deliver 68Ga3+ or 177Lu3+ to SSTR2-expressing neuroendocrine tumours, and PSMA-617 and PSMA-11 (bottom), containing the DOTA and HBED chelators respectively. 177Lu-PSMA-617 and 68Ga-PSMA-11 are theranostic radiopharmaceuticals used for treatment of PSMA-expressing prostate cancer.

In prostate cancer, the prostate specific membrane antigen (PSMA) is targeted most typically with a urea-containing dipeptide, appended to a PET isotope (68Ga, or 18F) or a radiotherapeutic isotope. The most common pairing is “68Ga-PSMA-11”, using a derivative of the HBED (bis(2-hydroxybenzyl)ethylenediaminediacetic acid) chelator, for diagnostic PET imaging, alongside companion “177Lu-PSMA-617”, using the DOTA chelator, for systemic radiotherapy (Figure 1) (Sartor et al., 2021).

There are a range of new therapeutic radionuclides that are being investigated for the utility of their β-, α and Auger electron particle emissions in cancer treatment. This is likely to have further impact in oncology treatment, and pharmaceutical investment in receptor-targeted cancer theranostics is in the multibillion dollar range (Sullivan et al., 2024). The availability of companion diagnostic agents will be critical to the clinical success of these future radiotherapy treatments. Currently, receptor-targeted PET agents are the state-of-the-art in molecular imaging, however, there are limitations here:

  • There are shortfalls in availability of 68Ga, as a result of demand for 68Ga outstripping supply (Kumar, 2020).
  • Whilst the development of 18F-labelled radiotracers for imaging PSMA in prostate cancer can potentially mitigate 68Ga-HBED-PSMA supplies, this is subject to existing limitations of PET/CT. First, many healthcare settings do not have access to PET/CT scanners (Sh and into, 2017; Verduzco-Aguirre et al., 2019; Al-Ibraheem et al., 2025). Second, 18F, which is produced in cyclotrons, has a half-life of 109 min, and so 18F PET radiopharmaceuticals are prepared onsite at hospitals or at centralised distribution facilities. Current radiosyntheses require multistep reactions and procedures, prolonged reaction times at high temperatures, and purification to remove unreacted radionuclide and other components. This necessitates costly equipment and highly trained staff. This can lead to shortages in radiopharmaceutical supply, disruption to patient treatment and geographical disparities in availability. In many lower to middle income countries, the costs, infrastructure and resources associated with 18F and PET/CT are barriers to implementation (Al-Ibraheem et al., 2025).

There is an alternative to complex radiopharmaceutical production: one-step, rapid, kit-based radiosyntheses of radiopharmaceuticals, which decrease the need for infrastructure, personnel and expense. This approach is already applied with “traditional” technetium-99m (99mTc). 99mTc emits γ-photons (t ½ = 6 h; 90% γ, 140 keV) and is widely used in γ-scintigraphy and SPECT imaging radiopharmaceuticals for perfusion/function imaging. 99mTc is universally available from 99Mo/99mTc generators, with well-established supply chains from nuclear reactors, and 99mTc radiopharmaceuticals are routinely prepared by technicians in radiopharmacies, using aqueous 99mTc, commercial “kits” (containing reagents and chelator) and a syringe. The chelators rapidly bind 99mTc, enabling simple radiosyntheses (Jackson et al., 2020; Rivas et al., 2021).

Due to all these existing resources, 99mTc imaging is significantly more accessible than PET imaging. For example, it is estimated that 99mTc is used in over 30 million scans worldwide per year. In the UK, there are 252 National Health Service (NHS) nuclear medicine departments (as of 2021), which routinely undertake 99mTc imaging procedures. From 2013 to 2023 within NHS England, there were 4,263,180 γ-scintigraphy and SPECT scans undertaken, and 1,621,835 PET/CT scans (NHS England, 2023).

The development of molecular 99mTc radiopharmaceuticals would leverage existing healthcare and infrastructure resources, enabling increased population-wide access to receptor-targeted molecular imaging. These resources include SPECT and γ-scintigraphy cameras, which are more prevalent than PET/CT cameras (Weber et al., 2023; Bodei et al., 2022; Shi et al., 1998). Essential resources, including trained staff, radiopharmacies and nuclear medicine infrastructure, already exist.

The β--emitting radioisotope, 188Re, is also available from a benchtop 188W/188Re generator, and the β- decay properties (t ½ = 17 h; 100% β−, E max = 2.12 MeV; 15% γ, 155 keV) of 188Re are suitable for systemic radiotherapy (Lepareur et al., 2019). Furthermore, systemic radiotherapeutics are potentially economically viable and accessibly in Lower and Middle Income Countries (LMICs), where there are significant barriers to accessing radiopharmaceuticals (Shinto, 2017; Bernal et al., 2008). Recognising the potential of 188Re as an affordable basis for systemic radiotherapies, in the early part of this century, the International Atomic Energy Agency (IAEA) sponsored multinational clinical trials of 188Re-labelled Lipiodol for treatment of inoperable liver cancer in LMICs (including India, Mongolia, Philippines, Thailand and Vietnam). 188Re-labelled Lipiodol proved effective and inexpensive (Bernal et al., 2008; Bernal et al., 2007). 188Re-labelled bisphosphonates have also been extremely beneficial in palliative treatment of bone metastases in LMICs (Shinto et al., 2018). 188W/188Re generators currently supply 188Re for “Rhenium-SCT” brachytherapy (Baxi et al., 2024) for highly prevalent basal and squamous cell carcinomas, the most common skin cancers. “Rhenium-SCT” has been recently approved in Europe, South Africa and Australia.

Tc and Re often form isostructural and isoelectronic complexes, leading to the possibility of pairs of complexes with near identical biodistributions, including accumulation patterns in diseased tissue, in vivo. Pairs of 99mTc and 188Re radiopharmaceuticals are often considered “theranostic pairs”, with the 99mTc radiotracer providing a diagnostic image of disease, to stratify patients for systemic radiotherapy using an analogous 188Re radiotracer (Blower et al., 2000; Bordoloi et al., 2015; Spyrou et al., 2021).

99mTc chemistry and its application has been a dynamic and international field of research for the last 8 decades, and alongside the routine clinical use of 99mTc perfusion and anatomical radiopharmaceuticals, there are many elegant examples of 99mTc tracers that have entered first-in-human studies (Alberto, 2023a; Alberto, 2023b; Riondato et al., 2023; Duatti, 2021; Shi and Liu, 2024). This review will summarise how well-established 99mTc chelator and coordination chemistry, such as that used for 99mTc perfusion imaging agents, has been applied to develop the latest state-of-the-art radiopharmaceuticals that have recently entered clinical evaluation for receptor targeted imaging. It will also describe selected innovations in ligands designed specifically for 99mTc that demonstrate the breadth and scope of Tc coordination chemistry.

MAG3 and mas3 radiotracers

The “MAG3” (mercaptoacetyl-triglycine) chelator consists of a mercapto function attached to three glycine amino acids. The deprotonated amide groups in combination with the thiol donor group provide a N3S tetradentate chelator that coordinates a [99mTcVO]3+ motif, to furnish a five-coordinate, distorted square pyramidal complex, [99mTcO(MAG3)]- (Grummon et al., 1995), used routinely for diagnostic renal imaging (Figure 2) (Marta et al., 2013).

Structures of [<sup>99m</sup>TcO(MAG<sub>3</sub>)]<sup>-</sup> and <sup>99m</sup>Tc-PSMA-I&S.
Figure 2. Structures of [99mTcO(MAG3)]- and 99mTc-PSMA-I&S.

The chemistry of [99mTcO(MAG3)]- has been successfully adapted for molecular imaging. Early studies established that glycine residues can be substituted for other amino acids without ameliorating [99mTcVO]3+ coordination (Cantorias et al., 2007; Cyr et al., 2007). NMR experiments have indicated that in this case, in which glycine is substituted for optically active amino acids, two distinct isomers are formed, as the amino acid sidechains can be positioned either syn or anti relative to the Tc=O bond (Cantorias et al., 2007; Cyr et al., 2007).

The most significant application of this chemistry to 99mTc molecular imaging involves replacement of the three glycine amino acids for serine amino acids, and concomitant functionalisation with PSMA-targeted peptide sequences (Figure 2) (Robu et al., 2017). It is notable that incorporation of “unnatural” D-serine in place of biogenic L-serine results in increased metabolic stability of the 99mTc radiotracer.33 99mTc-PSMA-I&S is the most clinically studied of these mas3-derived PSMA-targeted tracers to date. 99mTc-PSMA-I&S has demonstrated utility in detecting tumour lesions at various stages of prostate cancer, including primary and advanced disease, and in biochemically recurrent prostate cancer (Werner et al., 2020). However, when lesions are small or the biochemical markers of recurrence are low, 99mTc-PSMA-I&S imaging detects fewer lesions than PSMA PET imaging (Albalooshi et al., 2020). 99mTc-PSMA-I&S has also been clinically assessed for detection of prostate cancer metastases using a hand-held γ-detector, during surgery. The aim of this endeavour is to improve surgical resection of prostate cancer tissue (Maurer et al., 2019).

More recently, a new PSMA-targeted mas3-peptide derivative, PSMA-GCK01,37 has been developed for coordination of both the [99mTcO]3+ and [188ReO]3+ motifs. In a first in human study, both tracers showed equivalent biodistributions in a prostate cancer patient, as evidenced by γ-scintigraphy (Figure 3). Such innovation shows the feasibility and possibility of chemically analogous 99mTc/188Re dual molecular imaging/systemic radiotherapy tracers.

γ-Scintigraphy shows similar biodistribution patters of <sup>99m</sup>Tc-PSMA-GCK01 and <sup>188</sup>Re-PSMA-GCK01 in a prostate cancer patient. This image is reproduced from Cardinale et al. (2023) under a Creative Commons Attribution 4.0 International License, copyright SNMMI.
Figure 3. γ-Scintigraphy shows similar biodistribution patters of 99mTc-PSMA-GCK01 and 188Re-PSMA-GCK01 in a prostate cancer patient. This image is reproduced from Cardinale et al. (2023) under a Creative Commons Attribution 4.0 International License, copyright SNMMI.

New directions, including application of mercapto-peptide chelating derivatives to alternative pharmacophores and their receptor targets – for example, small molecules that target cancer-associated fibroblasts of aggressive, hard-to-treat cancers — will further expand the clinical utility of this chelator chemistry (Xu et al., 2025).

HMPAO and maraciclatide

Like MAG3, HMPAO (hexamethylpropylene amine oxine) coordinates a [99mTcVO]3+ core (Figure 4). The resulting neutral, lipophilic complex can pass the blood-brain barrier, and [99mTcO(HMPAO)] is routinely used to detect changes in cerebral perfusion in stroke patients (Neirinckx et al., 1987).

Structures of [<sup>99m</sup>TcO(MAG<sub>3</sub>)]<sup>-</sup> and <sup>99m</sup>Tc-PSMA-I&S.
Figure 4. Structures of [99mTcO(MAG3)]- and 99mTc-PSMA-I&S.

The radiopharmaceutical “99mTc-maraciclatide” is a derivative of HMPAO. In this 99mTc-labelled compound, the HMPAO chelator contains two additional methyl substituents, and is appended to a cyclic “RGD” peptide that targets the αvβ3 integrin receptor (Figure 4), which is associated with inflammation and neovasculature. 99mTc-maraciclatide has been assessed in multiple first-in-human studies, and has shown utility for clinical imaging in imaging rheumatoid arthritis (Attipoe et al., 2020), cancer imaging (Cook et al., 2018) and more recently, in endometriosis, for which it has recently received FDA fast track designation.

HYNIC

The HYNIC motif, 2-hydrazinonicotinamide, was pioneered in the 1990s (Abrams et al., 1990), and acts as both the linker and a chelator. The coordination environment of 99mTc complexes has not been elucidated despite HYNIC’s prevalent use. Scientific literature often depicts HYNIC coordinating to TcV in a monodentate fashion (Figure 5), with five co-ligands for stabilization — for example, ethylenediaminediacetic acid (EDDA) — although existing data suggests that it is more likely to interact with Tc as a bidentate chelator, via the terminal hydrazine and pyridine nitrogen atom, with the latter requiring fewer co-ligands to fill the Tc coordination sphere (King et al., 2007; Meszaros et al., 2010). Attempts to prepare Re analogues of Tc complexes have largely been unsuccessful. Despite this, the radiopharmaceutical 99mTc-EDDA/HYNIC-octreotide is in occasional use for receptor targeted imaging of the somatostatin receptor over-expressed in neuroendocrine cancers (Gabriel et al., 2003), and 99mTc-HYNIC derivatives targeting αvβ3 integrin (Zhu et al., 2012) and PSMA (Lawal et al., 2017) have recently undergone clinical studies in cancer imaging.

The structure of HYNIC, and a possible structure of <sup>99m</sup>Tc-EDDA/HYNIC-octreotide.
Figure 5. The structure of HYNIC, and a possible structure of 99mTc-EDDA/HYNIC-octreotide.

Organometallic complexes of 99mTcI

Organometallic complexes of 99mTcI have exhibited sufficient kinetic stability to enable application in radiopharmaceuticals, and indeed, are useful exemplars in demonstrating the application of organometallic chemistry to healthcare. The homoleptic 99mTc complex, 99mTc-sestamibi, consists of six isonitrile ligands coordinated to a TcI metal centre in an octahedral environment (Figure 6) (Kronauge and Mindiola, 2016). The resulting lipophilic complex bearing a single positive charge, diffuses across the lipid bilayer of cell and then mitochondrial membranes, driven by membrane potentials. As 99mTc-sestamibi accumulates in tissue rich in mitochondria, such as the heart, 99mTc-sestamibi is routinely used for imaging cardiac perfusion.

Structures of <sup>99m</sup>Tc<sup>I</sup>-sestamibi, *fac*-[<sup>99m</sup>Tc<sup>I</sup>(CO)<sub>3</sub>(H<sub>2</sub>O)<sub>3</sub>]<sup>+</sup> and MIP-1404, which coordinates to *fac*-[<sup>99m</sup>Tc<sup>I</sup>(CO)<sub>3</sub>]<sup>+</sup> via three N donors (highlighted in blue).
Figure 6. Structures of 99mTcI-sestamibi, fac-[99mTcI(CO)3(H2O)3]+ and MIP-1404, which coordinates to fac-[99mTcI(CO)3]+ via three N donors (highlighted in blue).

Although they have not been assessed in the clinical, isonitrile ligands bearing receptor-targeted peptides have been developed for coordination to 99mTcI (Mizuno et al., 2016). This approach, whereby multiple copies of a targeting motif are incorporated onto a single radioactive metal centre, is potentially advantageous in increasing the affinity of a molecular radiopharmaceutical for its cognate receptor.

At the turn of the century, the d6 fac-[99mTcI(CO)3(H2O)3]+ complex was developed (Alberto et al., 2001; Alberto et al., 1998). The three water ligands undergo relatively rapid substitution, enabling coordination of chelator-pharmacophore bioconjugates. The fac-[99mTcI(CO)3]+ motif is used in the radiopharmaceutical 99mTc-MIP-1404 (also known as 99mTc-Trofolastat), in which the PSMA-targeted dipeptide is appended to a tridentate N3 chelator consisting of a tertiary amine with two pendant imidazole groups, which in turn is coordinated to the fac-[99mTcI(CO)3]+ motif, to form an octahedral complex (Figure 6) (Hillier et al., 2013) The radiosynthesis and purification of 99mTc-MIP-1404 is currently time-consuming compared to kit formulations of 99mTc perfusion radiopharmaceuticals: the former requires (i) formation of an intermediate fac-[99mTc(CO)3(H2O)3]+ precursor prior to (ii) chelation with the tridentate MIP-1404 chelator-peptide, and finally (iii) purification and formulation before administration.

99mTc-MIP-1404 has demonstrated clinical utility for detection of prostate cancer lesions in patients with intermediate and high grade prostate cancer before prostatectomy (Goffin et al., 2017), and in patients with biochemical recurrence of prostate cancer (after primary treatment with either prostatectomy or radiotherapy) (Schmidkonz et al., 2018). Recent clinical studies have confirmed its suitability as a companion diagnostic imaging agent to inform stratification of patients for systemic radiotherapy with 177Lu-DOTA-PSMA (Derlin et al., 2025; Cook et al., 2023). As a result, 99mTc-MIP-1404 has recently been approved by the United Kingdom’s MHRA for clinical use in imaging and detecting high risk prostate cancer, biochemical recurrence of prostate cancer, and in assessing eligibility for 177Lu-DOTA-PSMA systemic radiotherapy.

Other elegant organometallic 99mTc complexes have been developed, and although, like isonitrile-peptide derivatives for coordination of 99mTcI (Mizuno et al., 2016), they have not yet been assessed in clinical studies, their ingenuity compels a mention. This includes piano-stool fac-[99mTcI(CO)3]+ complexes based on cyclopentadiene motifs bearing receptor-targeted peptides (Frei et al., 2019), dinuclear Tc complexes such as [99mTc2(μ2-SR)3(CO)6]- (R = S(CH2)2NEt2), bridged by alkyl thiols (Bolliger et al., 2019), and [Tc(η6-arene)2]+ sandwich complexes (Nadeem et al., 2020), including those of functionalised arenes that have exhibited anti-tumour activity (Battistin et al., 2023).

Phosphine complexes

The 99mTcV complex, 99mTc-tetrofosmin, consists of a [TcO2]+ motif coordinated to two bidentate diphosphine ligands, to furnish a lipophilic, singly charged cation, which, like 99mTc-sestamibi, is routinely used for imaging cardiac perfusion (Jones and Hendel, 1993). Like 99mTc-HMPAO, 99mTc-sestamibi and 99mTc-MAG3, 99mTc-tetrafosmin can be prepared using a single step kit, in which all the non-radioactive reagents are contained in a lyophilised, sterile vial, to which generator-produced 99mTcO4 - is added, to furnish 99mTc-tetrofosmin, typically in quantitative radiochemical yield.

Inspired by the efficiency of the kit-based radiosynthesis of 99mTc-tetrofosmin, we have recently developed diphosphine-derivatised maleic anhydride platforms to prepare bioconjugates of diphosphines with receptor-targeted molecules (targeting αvβ3 integrin (Hungnes et al., 2021), PSMA receptors (Hungnes et al., 2023; Pham et al., 2024; Nuttall et al., 2025)) and other receptors (Nuttall et al., 2025) (Figure 7). These diphosphine-based bioconjugates can be incorporated into a kit formulation (Hungnes et al., 2021; Hungnes et al., 2023; Pham et al., 2024; Nuttall et al., 2025; Nuttall et al., 2023). Addition of 99mTcO4 - in saline to a lyophilised mixture of the diphosphine-peptide, reducing agent (stannous chloride), intermediate chelator (tartrate) and buffer (carbonate), yields the desired radiotracer, [99mTcO2(DP-peptide)2]+ in high radiochemical yields.

Preparation of diphosphine (DP) bioconjugates and resultant <sup>99m</sup>Tc/<sup>188</sup>Re-labelled radiotracers, using diphosphine-derivatise maleic anhydride platforms. Here, we have presented a SPECT/CT image of a mouse bearing a PSMA-positive DU145 prostate cancer tumour, 2 h post-injection of a PSMA-targeted exemplar, [<sup>99m</sup>TcO<sub>2</sub>(DP-PSMAt)<sub>2</sub>]<sup>+</sup> (where Ar = *p*-C<sub>6</sub>H<sub>4</sub>(CH<sub>3</sub>).
Figure 7. Preparation of diphosphine (DP) bioconjugates and resultant 99mTc/188Re-labelled radiotracers, using diphosphine-derivatise maleic anhydride platforms. Here, we have presented a SPECT/CT image of a mouse bearing a PSMA-positive DU145 prostate cancer tumour, 2 h post-injection of a PSMA-targeted exemplar, [99mTcO2(DP-PSMAt)2]+ (where Ar = p-C6H4(CH3).

By tuning phosphine ligand substituents of a diphosphine maleic anhydride derivative to increase electron donation of the phosphine ligands, we have shown that we can increase the radiochemical yield of the desired [99mTcO2(DP-peptide)2]+ radiotracer (Hungnes et al., 2023; Nuttall et al., 2025). Furthermore, chemically analogous [188ReO2(DP-peptide)2]+ compounds can also be accessed, using generator-produced 188Re, and pairs of 99mTc and 188Re radiotracers show near-equivalent biodistributions in mouse models of cancer (Pham et al., 2024). To date, the radiotracers we have prepared all show high tumour accumulation, fast clearance via a renal pathway and low off-target/healthy organ retention (Hungnes et al., 2021; Pham et al., 2024; Nuttall et al., 2025; Nuttall et al., 2023), suggesting that diphosphine platforms have utility for simple, kit-based preparation of 99mTc radiopharmaceuticals.

Concluding remarks

Chemical technology enabling development and clinical adoption of 99mTc receptor-targeted molecular imaging has demonstrated feasibility for clinical translation, and new, fit-for-purpose innovations in 99mTc and 188Re chelator chemistry could enable the development of 99mTc and 188Re receptor-targeted theranostic pairs. These advances match the availability of existing nuclear medicine infrastructure, including 99mTc generator supply chains, γ-scintigraphy and SPECT cameras, and radiopharmacies and nuclear medicine departments. The latter include staff skilled in formulation of kit-based 99mTc radiopharmaceuticals. Leveraging 99mTc chemistry alongside these resources and infrastructure could increase economical and accessible patient access to the benefits of molecular radiopharmaceuticals.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited by: Craig C. McLauchlan, Illinois State University, United States

Reviewed by: Roger Alberto, University of Zurich, Switzerland

Oliver Kiß, Helmholtz Association of German Research Centers (HZ), Germany

Statements

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

The author(s) declared that financial support was received for this work and/or its publication: MTM is grateful for the support of a Cancer Research UK Career Establishment Award (C63178/A24959).

Author contributions

MTM: Writing – original draft, Writing – review and editing.

References

  1. Abrams M. J., Juweid M., TenKate C. I., Schwartz D. A., Hauser M. M., Gaul F. E. (1990). Technetium-99m-Human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med. 31, 2022 – 2028.
  2. Al-Ibraheem A., Brink A., Lee S. T., De Los Reyes A., Paez D., Craviolatti P. S. (2025). Implementation of radiotheranostics: challenges, barriers, and IAEA-driven strategies for sustainable access. Semin. Nucl. Med. 55, 1032 – 1044. doi:10.1053/j.semnuclmed.2025.07.005
  3. Albalooshi B., Al sharhan M., Bagheri F., Miyanath S., Ray B., Muhasin M. (2020). Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer. Asia Ocean. J. Nucl. Med. Biol. 8, 1 – 7. doi:10.22038/aojnmb.2019.43943.1293
  4. Alberto R. (2023a). From carbonyls to π-Aromatic arenes: a thirty years journey through organometallic technetium chemistry. J. Organomet. Chem. 1000, 122828. doi:10.1016/j.jorganchem.2023.122828
  5. Alberto R. (2023b). Role of pure technetium chemistry: are there still links to applications in imaging? Inorg. Chem. 62, 20539 – 20548. doi:10.1021/acs.inorgchem.3c01620
  6. Alberto R., Schibli R., Egli A., Schubiger A. P., Abram U., Kaden T. A. (1998). A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [ 99m Tc(OH 2) 3 (CO) 3 ] + from [ 99m TcO 4 ] - in aqueous solution and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987 – 7988. doi:10.1021/ja980745t
  7. Alberto R., Ortner K., Wheatley N., Schibli R., Schubiger A. P. (2001). Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [ 99m Tc(OH 2) 3 (CO) 3 ] +. J. Am. Chem. Soc. 123, 3135 – 3136. doi:10.1021/ja003932b
  8. Attipoe L., Chaabo K., Wajed J., Hassan F. U., Shivapatham D., Morrison M. (2020). Imaging neoangiogenesis in rheumatoid arthritis (INIRA): whole-body synovial uptake of a 99m Tc-Labelled RGD peptide is highly correlated with power doppler ultrasound. Ann. Rheum. Dis. 79, 1254 – 1255. doi:10.1136/annrheumdis-2020-217228
  9. Battistin F., Fernandes C., Raposinho P. D., Blacque O., Paulo A., Alberto R. (2023). In vivo and in vitro studies of [M(η 6 -Pseudoerlotinib) 2 ] + sandwich complexes (M = Re, 99m Tc). Dalt. Trans. 52, 15757 – 15766. doi:10.1039/d3dt03011c
  10. Baxi S., Vohra S., Hong A., Mulholland N., Heuschkel M., Dahlhoff G. (2024). Effectiveness and patient experiences of rhenium skin cancer therapy for nonmelanoma skin cancer: interim results from the EPIC-skin study. J. Nucl. Med. 65, 1450 – 1455. doi:10.2967/jnumed.124.267988
  11. Bernal P., Raoul J. L., Vidmar G., Sereegotov E., Sundram F. X., Kumar A. (2007). Intra-arterial Rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int. J. Radiat. Oncol. Biol. Phys. 69, 1448 – 1455. doi:10.1016/j.ijrobp.2007.05.009
  12. Bernal P., Raoul J.-L., Stare J., Sereegotov E., Sundram F. X., Kumar A. (2008). International atomic energy agency-sponsored multination study of intra-arterial Rhenium-188-Labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin. Nucl. Med. 38, S40 – S45. doi:10.1053/j.semnuclmed.2007.10.006
  13. Blower P. J., Kettle A. G., O’Doherty M. J., Coakley A. J., Knapp F. F. (2000). 99mTc(V)DMSA quantitatively predicts 188 Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur. J. Nucl. Med. 27, 1405 – 1409. doi:10.1007/s002590000307
  14. Bodei L., Herrmann K., Schöder H., Scott A. M., Lewis J. S. (2022). Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 19, 534 – 550. doi:10.1038/s41571-022-00652-y
  15. Bolliger R., Frei A., Braband H., Meola G., Spingler B., Alberto R. (2019). Chemistry at high dilution: dinuclear 99 MTc complexes. Chem. - A Eur. J. 25, 7101 – 7104. doi:10.1002/chem.201901161
  16. Bordoloi J. K., Berry D., Khan I. U., Sunassee K., De Rosales R. T. M., Shanahan C. (2015). Technetium-99m and Rhenium-188 complexes with one and two pendant bisphosphonate groups for imaging arterial calcification. Dalt. Trans. 44, 4963 – 4975. doi:10.1039/c4dt02965h
  17. Cantorias M. V., Howell R. C., Todaro L., Cyr J. E., Berndorff D., Rogers R. D. (2007). MO tripeptide diastereomers (M = 99/99m Tc, re): models to identify the structure of 99m Tc peptide targeted radiopharmaceuticals. Inorg. Chem. 46, 7326 – 7340. doi:10.1021/ic070077p
  18. Cardinale J., Giesel F. L., Wensky C., Rathke H. G., Haberkorn U., Kratochwil C. (2023). PSMA-GCK01 - A generator-based 99m Tc-/ 188 Re-Theranostic ligand for the prostate-specific membrane antigen. J. Nucl. Med. 64, 1069 – 1075. doi:10.2967/jnumed.122.264944
  19. Cook G. J. R., Azad G. K., Taylor B. P., Lee E., Morrison M. S., Hughes S. (2018). Imaging αvβ3 integrin expression in skeletal metastases with 99m Tc-Maraciclatide single-photon emission computed tomography: detection and therapy response assessment. Eur. J. Nucl. Med. Mol. Imaging 45, 898 – 903. doi:10.1007/s00259-017-3926-7
  20. Cook G. J. R., Wong W. L., Sanghera B., Mangar S., Challapalli A., Bahl A. (2023). Eligibility for 177 Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of 68 Ga-PSMA-11 and 99m Tc-MIP-1404 in metastatic castration-resistant prostate cancer. J. Nucl. Med. 64, 227 – 231. doi:10.2967/jnumed.122.264296
  21. Cyr J. E., Pearson D. A., Nelson C. A., Lyons B. A., Zheng Y., Bartis J. (2007). Isolation, characterization, and biological evaluation of syn and anti diastereomers of [ 99m Tc]Technetium depreotide: a somatostatin receptor binding tumor imaging agent. J. Med. Chem. 50, 4295 – 4303. doi:10.1021/jm060887v
  22. Derlin T., Widjaja L., Harke N. N., Czerner C., Weiberg D., Ross T. L. (2025). 99mTc-MIP-1404 SPECT/CT companion diagnostic for 177 Lu-PSMA therapy in metastatic castration-resistant prostate cancer. J. Nucl. Med. 66, 366 – 372. doi:10.2967/jnumed.124.269319
  23. Duatti A. (2021). Review on 99m Tc radiopharmaceuticals with emphasis on new advancements. Nucl. Med. Biol. 92, 202 – 216. doi:10.1016/j.nucmedbio.2020.05.005
  24. Frei A., Fischer E., Childs B. C., Holland J. P., Alberto R. (2019). Two is better than one: difunctional high-affinity PSMA probes based on a [CpM(CO) 3 ] (M = Re/ 99m Tc) scaffold. Dalt. Trans. 48, 14600 – 14605. doi:10.1039/c9dt02506e
  25. Gabriel M., Decristoforo C., Donnemiller E., Ulmer H., Watfah Rychlinski C., Mather S. J. (2003). An intrapatient comparison of 99m Tc-EDDA/HYNIC-TOC with 111 In-DTPA-Octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med. 44, 708 – 716.
  26. Goffin K. E., Joniau S., Tenke P., Slawin K., Klein E. A., Stambler N. (2017). Phase 2 study of 99m Tc-Trofolastat SPECT/CT to identify and localize prostate cancer in Intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection. J. Nucl. Med. 58, 1408 – 1413. doi:10.2967/jnumed.116.187807
  27. Grummon G., Rajagopalan R., Palenik G. J., Koziol A. E., Nosco D. L. S. (1995). Characterization and crystal structures of Technetium(V)-Oxo complexes useful in nuclear medicine. 1. Complexes of mercaptoacetylglycylglycylglycine (MAG3) and its methyl ester derivative (MAG3OMe). Inorg. Chem. 34, 1764 – 1772. doi:10.1021/ic00111a025
  28. Hillier S. M., Maresca K. P., Lu G., Merkin R. D., Marquis J. C., Zimmerman C. N. (2013). 99m Tc-Labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J. Nucl. Med. 54, 1369 – 1376. doi:10.2967/jnumed.112.116624
  29. Hungnes I. N., Al-Salemee F., Gawne P. J., Eykyn T., Atkinson R. A., Terry S. Y. A. (2021). One-step, kit-based radiopharmaceuticals for molecular SPECT imaging: a versatile diphosphine chelator for 99m Tc radiolabelling of peptides. Dalt. Trans. 50, 16156 – 16165. doi:10.1039/d1dt03177e
  30. Hungnes I. N., Pham T. T., Rivas C., Jarvis J. A., Nuttall R. E., Cooper S. M. (2023). Versatile diphosphine chelators for radiolabeling peptides with 99m Tc and 64 Cu. Inorg. Chem. 62, 20608 – 20620. doi:10.1021/acs.inorgchem.3c00426
  31. Jackson J. A., Hungnes I. N., Ma M. T., Rivas C. (2020). Bioconjugates of chelators with peptides and proteins in nuclear medicine: historical importance, current innovations, and future challenges. Bioconjugate Chem. 31, 483 – 491. doi:10.1021/acs.bioconjchem.0c00015
  32. Jones S., Hendel R. C. (1993). Technetlum-99m tetrofosmin: a new myocardial perfusion. J. Nucl. Med. Technol. 21, 191 – 196.
  33. King R. C., Surfraz M. B. U., Biagini S. C. G., Blower P. J., Mather S. J. (2007). How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalt. Trans. 43, 4998 – 5007. doi:10.1039/b705111e
  34. Kronauge J. F., Mindiola D. J. (2016). The value of stable metal–carbon bonds in nuclear medicine and the cardiolite story. Organometallics 35, 3432 – 3435. doi:10.1021/acs.organomet.6b00618
  35. Kumar K. (2020). The current status of the production and supply of Gallium-68. Cancer Biother Radiopharm. 35, 163 – 166. doi:10.1089/cbr.2019.3301
  36. Langbein T., Weber W. A., Eiber M. (2019). Future of theranostics: an outlook on precision oncology in nuclear medicine. J. Nucl. Med. 60, 13S – 19S. doi:10.2967/jnumed.118.220566
  37. Lawal I. O., Ankrah A. O., Mokgoro N. P., Vorster M., Maes A., Sathekge M. M. (2017). Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate 77, 1205 – 1212. doi:10.1002/pros.23379
  38. Lepareur N., Lacœuille F., Bouvry C., Hindré F., Garcion E., Chérel M. (2019). Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives. Front. Med. 6, 132. doi:10.3389/fmed.2019.00132
  39. Marta S., Hiromoto K., Alves Togni P. H., dos Santos M. J. (2013). “ Clinical applications of nuclear medicine,” in Medical imaging in clinical practice. Editor F. O. Erondu (InTech), 37 – 62. doi:10.5772/45925
  40. Maurer T., Robu S., Schottelius M., Schwamborn K., Rauscher I., van den Berg N. S. (2019). 99m Technetium-Based prostate-specific membrane antigen–radioguided surgery in recurrent prostate cancer. Eur. Urol. 75, 659 – 666. doi:10.1016/j.eururo.2018.03.013
  41. Meszaros L. K., Dose A., Biagini S. C. G., Blower P. J. (2010). Hydrazinonicotinic acid (HYNIC) – coordination chemistry and applications in radiopharmaceutical chemistry. Inorganica Chim. Acta 363, 1059 – 1069. doi:10.1016/j.ica.2010.01.009
  42. Mizuno Y., Uehara T., Hanaoka H., Endo Y., Jen C. W., Arano Y. (2016). Purification-free method for preparing Technetium-99m-Labeled multivalent probes for enhanced in vivo imaging of saturable systems. J. Med. Chem. 59, 3331 – 3339. doi:10.1021/acs.jmedchem.6b00024
  43. Nadeem Q., Meola G., Braband H., Bolliger R., Blacque O., Hernández-Valdés D. (2020). To sandwich technetium: highly functionalized bis-arene complexes [ 99m Tc(η 6 -Arene) 2 ] + directly from water and [ 99m TcO 4 ] −. Angew. Chem. Int. Ed. 59, 1197 – 1200. doi:10.1002/anie.201912994
  44. Neirinckx R. D., Canning L. R., Piper I. M., Nowotnik D. P., Pickett R. D., Holmes R. A. (1987). Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J. Nucl. Med. 28 (2), 191 – 202.
  45. NHS England (2023). Diagnostic imaging dataset annual statistical release 2022/23. Available online at: (Accessed October 10, 2025).
  46. Nuttall R. E., Pham T. T., Chadwick A. C., Hungnes I. N., Firth G., Heckenast M. A. (2023). Diphosphine bioconjugates via Pt(0)-Catalyzed hydrophosphination. A versatile chelator platform for Technetium-99m and Rhenium-188 radiolabeling of biomolecules. Inorg. Chem. 62, 20582 – 20592. doi:10.1021/acs.inorgchem.2c04008
  47. Nuttall R. E., Hungnes I. N., Pham T. T., Carter O. W. L., Rigby A., Patel N. (2025). Maleic anhydride derived diphosphines: adaptable chelators for receptor-targeted 99m Tc, 64 Cu and 188 Re radiotracers. Chem. Sci. 16, 17112 – 17126. doi:10.1039/d5sc02110c
  48. Pham T. T., Hungnes I. N., Rivas C., Cleaver J., Firth G., Blower P. J. (2024). Receptor-targeted peptide conjugates based on diphosphines enable preparation of 99m Tc and 188 Re Theranostic agents for prostate cancer. J. Nucl. Med. 65, 1087 – 1094. doi:10.2967/jnumed.124.267450
  49. Riondato M., Rigamonti D., Martini P., Cittanti C., Boschi A., Urso L. (2023). Oldie but goodie: is Technetium-99m still a treasure trove of innovation for medicine? A patents analysis (2000–2022). J. Med. Chem. 66, 4532 – 4547. doi:10.1021/acs.jmedchem.3c00148
  50. Rivas C., Jackson J. A., Hungnes I. N., Ma M. T. (2021). Radioactive metals in imaging and therapy. Compr. Coord. Chem. III, 706 – 740. doi:10.1016/b978-0-08-102688-5.00010-6
  51. Robu S., Schottelius M., Eiber M., Maurer T., Gschwend J., Schwaiger M. (2017). Preclinical evaluation and first patient application of 99m Tc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J. Nucl. Med. 58, 235 – 242. doi:10.2967/jnumed.116.178939
  52. Sartor O., de Bono J., Chi K. N., Fizazi K., Herrmann K., Rahbar K. (2021). Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091 – 1103. doi:10.1056/NEJMoa2107322
  53. Schmidkonz C., Hollweg C., Beck M., Reinfelder J., Goetz T. I., Sanders J. C. (2018). 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate 78, 54 – 63. doi:10.1002/pros.23444
  54. Shinto A. (2017). An overview of nuclear medicine and PET CT in India. Curr. Trends Clin. Med. Imaging 1, 91 – 94. doi:10.19080/CTCMI.2017.01.555573
  55. Shi J., Liu S. (2024). Clinical application of 99m Tc-Labeled peptides for tumor imaging: current status and future directions. iRadiology 2, 17 – 34. doi:10.1002/ird3.55
  56. Shi W., Johnston C. F., Buchanan K. D., Ferguson W. R., Laird J. D., Crothers J. G. (1998). Localization of neuroendocrine tumours with [ 111 In]DTPA-Octreotide scintigraphy (octreoscan): a comparative study with CT and MR imaging. QJM 91, 295 – 301. doi:10.1093/qjmed/91.4.295
  57. Shinto A. (2017). Rhenium 188: the poor Man’s yttrium. World J. Nucl. Med. 16, 1 – 2. doi:10.4103/1450-1147.198225
  58. Shinto M., Kameswaran M., Kamaleshwaran K., Joseph J., Radhakrishnan E., Upadhyay I. (2018). Clinical utility of 188 Rhenium-Hydroxyethylidene-1,1-Diphosphonate as a bone pain palliative in multiple malignancies. World J. Nucl. Med. 17, 228 – 235. doi:10.4103/wjnm.wjnm_68_17
  59. Spyrou B., Hungnes I. N., Mota F., Bordoloi J., Blower P. J., White J. M. (2021). Oxorhenium(V) and Oxotechnetium(V) complexes of N 3 S tetradentate ligands with a styrylpyridyl functional group: toward imaging agents to assist in the diagnosis of alzheimer’s disease. Inorg. Chem. 60, 13669 – 13680. doi:10.1021/acs.inorgchem.1c01992
  60. Strosberg J., El-Haddad G., Wolin E., Hendifar A., Yao J., Chasen B. (2017). Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125 – 135. doi:10.1056/NEJMoa1607427
  61. Sullivan B., Davis A., Bak P. (2024). The radiopharmaceutical Renaissance: radiating hope in cancer therapy. Nature, B13 – B15. doi:10.1038/d43747-024-00014-w
  62. Verduzco-Aguirre H. C., Lopes G., Soto-Perez-De-Celis E. (2019). Implementation of diagnostic resources for cancer in developing countries: a focus on PET/CT. Ecancermedicalscience 13, ed87. doi:10.3332/ecancer.2019.ed87
  63. Weber W. A., Barthel H., Bengel F., Eiber M., Herrmann K., Schafers M. (2023). What is theranostics? J. Nucl. Med. 64, 669 – 670. doi:10.2967/jnumed.123.265670
  64. Werner P., Neumann C., Eiber M., Wester H. J., Schottelius M. (2020). [ 99m Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 10, 45. doi:10.1186/s13550-020-00635-z
  65. Xu M., Song H., Cai J., Chen J., Wang C., Wang R. (2025). Design, structure optimization, and preclinical evaluation of 188 Re-Labeled FAPI for targeted radionuclide therapy. J. Med. Chem. 68, 12940 – 12949. doi:10.1021/acs.jmedchem.5c00837
  66. Zhu Z., Miao W., Li Q., Dai H., Ma Q., Wang F. (2012). 99m Tc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J. Nucl. Med. 53, 716 – 722. doi:10.2967/jnumed.111.098988

Citation

Ma, M. T. (2026). Receptor-targeted technetium-99m radiopharmaceuticals: increasing access to molecular imaging in healthcare. Frontiers in Chemical Biology, Volume 4. https://doi.org/
Received
Accepted
Published
Volume
4 - 2026

Copyright

Copyright © 2026 Ma.

License: https://creativecommons.org/licenses/by/4.0/

*Correspondence: Michelle T. Ma

Article metrics

Views
0
Downloads
0
Citations
0
Shares
0

Related articles

Original ResearchNanoprobe XRF analysis reveals the intracellular distribution of organometallic rhenium complexes with different directing ligandC. Rumancev, S. K. Vellas, A. Gräfenstein, D. Obitz, J. Garrevoet, G. Falkenberg, N. Metzler-Nolte, A. RosenhahnPerspectiveAdvances in enhanced sampling simulations of G-protein-coupled receptorsKeya Joshi, Victor Ayo Adediwura, Yinglong MiaoOriginal ResearchA bifunctional carborane-quinazoline combines tumor growth inhibition and boron delivery for boron neutron capture therapy in melanoma and non-small cell lung cancer modelsMaría Alejandra Dagrosa, Marina Carpano, Antonella Pastini, Estanislao Pavlik, Andrés Bechis, María Silvina Olivera, Pablo Vallecorsa, Belén Dávila, Luciano Parodi, Esther Yardena Salem, María Sol Espain, Agustina Mariana Portu, Laura Todaro, Alejandro Urtreger, Pablo Menendez, Hugo Cerecetto, Marcos Couto